Ratings Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Real-time Estimate Cboe BZX Other stock markets 12:03:41 2024-06-10 pm EDT			5-day change	1st Jan Change
5.285 ^USD	-0.28%		-1.77%	-41.43%

Jun. 07	ILJIN SNT Co Provides Information to Shareholders of Aurinia Pharmaceuticals	CI
Jun. 05	Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 91.38 and 11.2 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AURINIA PHARMACEUTICALS INC.	-41.43%	756M	C-
VERTEX PHARMACEUTICALS INCORPORATED	+18.09%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+13.19%	108B	B+
BIONTECH SE	-7.15%	24.21B	B+
ARGENX SE	+2.07%	22.78B	B
GENMAB A/S	-10.79%	17.96B	A-
WUXI APPTEC CO., LTD.	-41.74%	16.43B	A-
BEIGENE, LTD.	-12.73%	16.37B	B
NEUROCRINE BIOSCIENCES, INC.	+0.96%	13.58B	C+
SAREPTA THERAPEUTICS, INC.	+26.25%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes